Alastair has over 30 years' experience in the pharmaceutical, life science and biotech industries including 18 years as a main board director, 12 years as CEO and is currently Chairman of the South West Academic Health Science Network and a non-executive director of four healthcare companies. He has taken a number of products through the clinical trials process for companies including Lederle (now Pfizer) and Centocor (now J&J). He has led significant fund raising efforts including an IPO on UK’s main list and trade sales to Takeda in Japan and Stem Cells Inc. in the USA. He has also had a role in a UK government Office for Life Sciences initiative related to promoting cooperation between pharmaceutical companies and the NHS in clinical trials.
Commenting on the appointment Dr. Riddell said, “I am delighted to join the board of Nemesis and help the executive team with their ambitious plans for growth. Their groundbreaking technology, based on the latest CRISPR gene editing techniques, has the potential to reverse the major healthcare problem of antibiotic resistance. The impact it could have in re-activating existing antibiotics and assisting development of new antibiotics would be transformative on a global scale. Pre-clinical data look promising and the company is poised, with the right backing, to enter formal pre-clinical and clinical development. After these are complete the market potential is enormous. I look forward to playing my part in this endeavour.”
Frank Massam, Chief Executive of Nemesis, said: “We are excited to add Alastair to our board and we are confident that his experience and industry-wide network will be enormously helpful to Nemesis as we plan and navigate the company’s aggressive growth and development plans”.
About Nemesis Bioscience Ltd
Nemesis Bioscience Ltd was founded in March 2014 by Dr Frank Massam, Professor Conrad Lichtenstein and Dr Gi Mikawa. Based in Cambridge and Cardiff, UK, the company has invented, and is developing, pioneering products that will resurrect anti-microbial therapies made ineffective by increasing microbial resistance. Nemesis Symbioticsã will impact one of the world’s most significant clinical problems by not only treating antibiotic resistant infections, but also by preventing them in susceptible patients. Large and rapidly growing opportunities exist for the company’s products in the antibiotic, wound care and veterinary medicine markets.
For more information please contact Dr. Frank Massam +44 7786 367053 or visit www.nemesisbio.com
________________________________________________